Search Results 51-60 of 94 for ⚔sbc가입코드 [원탑보증.com/가입코드 111] 레볼루션 ⚔

  1. Efficacy and Safety of Tislelizumab in Combination With Fruquintinib in Participants With Selected Solid Tumors - Mayo Clinic

    The purpose of this research is to see how well fruquintinib works in combination with tislelizumab in participants with metastatic colorectal cancer (mCRC).

  2. A Study to Evaluate a Standard-dose and High- dose Regimen of Encorafenib + Binimetinib in Patients with BRAFV600-mutant Melanoma Brain Metastasis - Mayo Clinic

    The purpose of this study is to assess the safety, effectiveness and pharmacokinetic (PK) of 2 dosing regimens of encorafenib + binimetinib combination in ...

  3. S0820, Adenoma and Second Primary Prevention Trial - Mayo Clinic

    About this study. The investigators hypothesize that the combination of eflornithine and sulindac will be effective in reducing a three-year event rate of ...

  4. Px Code,Supply #,Description,Unit Price 278000026,3643,KIT HEMODIALYSIS CATHETER POLYURETHANE DUAL LUMEN OVER THE WIRE SYMMETRIC TIP 14.5FRX19CM,498.12 ...

  5. Study of INTERCEPT Blood System for Red Blood Cells in Regions at Potential Risk for Zika Virus Transfusion-Transmitted Infections (RedeS) - Mayo Clinic

    Stage B: To provide early access to the INTERCEPT pathogen reduction system for RBC in regions where a substantial proportion of the population has been ...

  6. A Study of Belantamab Mafodotin (GSK2857916) in Multiple Myeloma Participants With Normal and Impaired Renal Function - Mayo Clinic

    Belantamab mafodotin (GSK2857916) is an antibody-drug conjugate (ADC) containing humanized anti- B-cell maturation antigen (BCMA) monoclonal antibody (mAb).

  7. Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer - Mayo Clinic

    About this study. This randomized phase III trial studies oxaliplatin, leucovorin calcium, fluorouracil, and bevacizumab to see how well they work compared ...

  8. DefenCath in Reducing Central Line-associated Bloodstream Infections (CLABSIs) in Adult Participants Receiving Total Parenteral Nutrition (TPN) - Mayo Clinic

    DefenCath in Reducing Central Line-associated Bloodstream Infections (CLABSIs) in Adult Participants Receiving Total Parenteral Nutrition (TPN) · Overview.

  9. Pazopanib in Treating Patients with Metastatic Non-Clear Cell Kidney Cancer - Mayo Clinic

    Pazopanib hydrochloride may also stop the growth of kidney cancer by blocking blood flow to the tumor. Participation eligibility. Participant eligibility ...

  10. Safety of MT-401-OTS in Patients with Relapsed AML or MDS - Mayo Clinic

    Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and ...